Phaseline

Companies › BlueRock Therapeutics

BlueRock Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Ophthalmology, Neurology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
bemdaneprocel
Midbrain dopaminergic neuron progenitors derived from human embryonic stem cells
THPhase 3Parkinsons Disease (PD)Oct 2028
OpCT-001
Photoreceptor precursor cells derived from human induced pluripotent stem cells (iPSCs)
–Phase 1Primary Photoreceptor DiseaseOct 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06944522bemdaneprocelPhase 3Parkinsons Disease (PD)NeurologyOct 2028
NCT06789445OpCT-001Phase 1Primary Photoreceptor DiseaseOphthalmologyOct 2029

Targets

TH (1)

Companies with the same targets

–

Companies built like this

AO GENERIUM Elpida Therapeutics SPC Beacon Therapeutics GenSight Biologics Ace Cells Lab

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.